Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lung Neoplasms × alectinib × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Thyroid Neoplasms 1 Lung Neoplasms 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1

Interventions

pembrolizumab 32 Carboplatin 23 Radiotherapy 21 Paclitaxel 17 Cisplatin 17 Erlotinib Hydrochloride 15 Docetaxel 14 Pemetrexed 11 Nivolumab 11 Gemcitabine 11 osimertinib 10 Etoposide 9 durvalumab 7 Radiosurgery 7 Magnetic Resonance Spectroscopy 7 atezolizumab 6 Specimen Handling 6 Cyclophosphamide 6 Cetuximab 5 Biopsy 5 Bevacizumab 5 130-nm albumin-bound paclitaxel 5 fludarabine 4 Taxes 4 Ipilimumab 4 Immunoglobulin G 4 Gefitinib 4 Albumin-Bound Paclitaxel 4 spartalizumab 3 epacadostat 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05987644 2026-03-09

DURABLE

Hoosier Cancer Research Network

Phase 1/2 Recruiting

Brain Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡